Quick Answer
Milestone Pharmaceuticals Inc. reported Diluted EPS of $0.75 per share (loss) for fiscal year 2025.
Milestone Pharmaceuticals Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.75 | -11.9% |
| 2024 | -$0.67 | +51.8% |
| 2023 | -$1.39 | -0.7% |
| 2022 | -$1.38 | -35.3% |
| 2021 | -$1.02 | +40.0% |
| 2020 | -$1.70 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.12 | +14.3% | +40.0% |
| June 30, 2025 | -$0.20 | -42.9% | +35.5% |
| March 31, 2025 | -$0.31 | -47.6% | -121.4% |
| September 30, 2024 | -$0.14 | +60.0% | +0.0% |
| June 30, 2024 | -$0.14 | +62.2% | +33.3% |
| March 31, 2024 | -$0.21 | +40.0% | +40.0% |
| September 30, 2023 | -$0.35 | -2.9% | +5.4% |
| June 30, 2023 | -$0.37 | +5.1% | -5.7% |
- Milestone Pharmaceuticals Inc. showed a decrease of -11.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Milestone Pharmaceuticals Inc.’s diluted eps has grown by 55.9% (from $1.70 per share (loss) to $0.75 per share (loss)).
- The most recent figure is from Milestone Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 20, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: